Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CreaVax-PC
- Development stage
- Phase 2
- Lead developer
- JW CreaGene
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
CreaVax-PC is an autologous dendritic cell-based cancer vaccine developed by JW CreaGene, often studied in collaboration with clinical centers such as Samsung Medical Center. The therapy is produced by harvesting a patient's own monocytes, which are then differentiated into dendritic cells ex vivo. These cells are matured and pulsed with prostate cancer-specific antigens and Keyhole Limpet Hemocyanin (KLH), which acts as an immunogenic carrier and adjuvant. Upon re-administration to the patient, these activated dendritic cells present the tumor antigens to the immune system, specifically inducing a T-cell mediated response (cytotoxic T lymphocytes) designed to target and destroy metastatic prostate cancer cells. It is primarily developed for patients with hormone-refractory metastatic prostate cancer (HRMPC) who have experienced PSA relapse.
- Brand names
- CreaVax-PC
- Other names
- Autologous dendritic cell vaccineCreaVax-PC vaccine
02
Targets
PAP (Prostatic acid phosphatase)HK3 (Hexokinase 3)PSA (Puromycin-sensitive aminopeptidase)
Beyond the preview
Go deeper on CreaVax-PC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CreaVax-PC.